Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

NCT07115667 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Solitary Bone Plasmacytoma
Plasmacytoma of Bone
Plasma Cell Disorders

Interventions

DRUG: BCMA/CD3 bispecific antibody (CM336)

Sponsor

Institute of Hematology & Blood Diseases Hospital, China